Natriuretic peptide desensitization in HF may relate, in part, to increased PDE activity, supporting a therapeutic role for PDE5 or PDE9 inhibition, especially among patients with advanced HF with blunted downstream response to natriuretic peptides.91 Here, PDE5A is linked to hydrops fetalis.